Objective. To find an effective, safe immunosuppressive regimen as an alternative to
cyclophosphamide (Cy) for the treatment of clinically evident diffuse scleroderma (dSSc) …

Objective We sought to determine the effectiveness of mycophenolate mofetil (MMF) in
scleroderma-associated interstitial lung disease (SSc-ILD). Methods We retrospectively …

Objective To compare mycophenolate mofetil (MMF) with placebo for the treatment of
systemic sclerosis (SSc)–related interstitial lung disease (ILD). Methods We included …

This study aims to determine the effectiveness of mycophenolate sodium (MS) in patients
with scleroderma (SSc)-related interstitial lung disease (ILD). In a prospective observational …

Background Scleroderma is a systemic autoimmune disease characterized mainly by skin
manifestations and involvement of various visceral organs, especially the lungs. Lung …

Up to 80% of patients with scleroderma have lung disease, with interstitial lung disease
(ILD) being the most common manifestation. Currently, there is no definitive therapy for this …

Objective. To report the efficacy and tolerability of mycophenolate mofetil (MMF) and
azathioprine (AZA) in the management of systemic sclerosis-associated interstitial lung …

Lung involvement constitutes nowadays the major cause of morbidity and mortality in
scleroderma patients. Pulmonary fibrosis in systemic sclerosis (SSc) is thought to be the …

Background 12 months of oral cyclophosphamide has been shown to alter the progression
of scleroderma-related interstitial lung disease when compared with placebo. However …

The efficacy and safety of mycophenolate mofetil (MMF) has been studied in patients with
systemic sclerosis (SSc)-related interstitial lung disease (ILD) with moderate–severe …